Search research articles
Contact Us
Filters
Showing results (291-300 of 436) with videos related to
Page
of 44
Sort By:
Nucleic Acids Research
|
September 15, 1996
Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence
M A Haidar, F Loya, Y Yang, et al.
Leukemia
|
December 1, 1996
Pneumonia during remission induction chemotherapy in patients with AML or MDS
M Wilhelm, H M Kantarjian, S O'Brien, et al.
The Journal of Infectious Diseases
|
October 1, 1983
Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients
V Fainstein, G P Bodey, K B McCredie, et al.
Hematology and Cell Therapy
|
December 1, 1996
Clinical experience with fludarabine in hemato-oncology
M J Keating, S O'Brien, P McLaughlin, et al.
Seminars in Oncology
|
October 1, 1993
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies
W Plunkett, V Gandhi, P Huang, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
October 24, 2000
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells
C O Rodriguez, W Plunkett, M T Paff, et al.
Annals of Internal Medicine
|
February 1, 1993
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine
M A Dimopoulos, H Kantarjian, E Estey, et al.
British Journal of Haematology
|
September 1, 1994
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen
H M Kantarjian, S O'Brien, T Smith, et al.
Cancer
|
April 8, 1999
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission
J E Cortes, H M Kantarjian, S O'Brien, et al.
Bone Marrow Transplantation
|
February 3, 2004
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics
I F Khouri, M Albitar, R M Saliba, et al.
Page
of 44
Search research articles
Search
Showing results (291-300 of 436) with videos related to
Sort By:
Page
of 44
Nucleic Acids Research
|
September 15, 1996
Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence
M A Haidar, F Loya, Y Yang, et al.
Leukemia
|
December 1, 1996
Pneumonia during remission induction chemotherapy in patients with AML or MDS
M Wilhelm, H M Kantarjian, S O'Brien, et al.
The Journal of Infectious Diseases
|
October 1, 1983
Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients
V Fainstein, G P Bodey, K B McCredie, et al.
Hematology and Cell Therapy
|
December 1, 1996
Clinical experience with fludarabine in hemato-oncology
M J Keating, S O'Brien, P McLaughlin, et al.
Seminars in Oncology
|
October 1, 1993
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies
W Plunkett, V Gandhi, P Huang, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications
|
October 24, 2000
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells
C O Rodriguez, W Plunkett, M T Paff, et al.
Annals of Internal Medicine
|
February 1, 1993
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine
M A Dimopoulos, H Kantarjian, E Estey, et al.
British Journal of Haematology
|
September 1, 1994
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen
H M Kantarjian, S O'Brien, T Smith, et al.
Cancer
|
April 8, 1999
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission
J E Cortes, H M Kantarjian, S O'Brien, et al.
Bone Marrow Transplantation
|
February 3, 2004
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics
I F Khouri, M Albitar, R M Saliba, et al.
Page
of 44